Alzheimer’s disease (AD) is an age-associated neurological disorder, accounting for 60–80% of all dementia cases [1], characterized by the presence of extracellular senile plaques formed by amyloid-β (Aβ) peptide and intracellular neurofibrillary tangles formed by hyperphosphorylated Tau protein as its two main hallmarks [2], as well as reduced glucose metabolism in the brain, neuroinflammation, extensive synaptic loss and neuronal loss in vulnerable brain areas [3,4,5]. Here, MAPT is linked to Alzheimer disease.